A new preclinical study suggests that gene augmentation therapy may restore sight in a severe form of inherited night blindness. The work, reported in Gene Therapy, targets complete congenital stationary night blindness (cCSNB), a disorder in which the retinal circuitry fails to generate reliable visual responses from birth. In mouse models, treatment improved both retinal function and visual performance, offering a promising blueprint for future human therapies.

The researchers focused on augmenting gene activity to compensate for the underlying molecular defect driving defective photoreceptor signaling. Rather than attempting to edit the genome directly, the approach delivers functional genetic instructions to retinal cells, aiming to re-establish healthier visual transduction. This strategy is designed for conditions where disease-causing pathways can be partially rescued by restoring protein expression levels.

Using viral delivery, the team administered a therapeutic vector into the eyes of affected mice. After treatment, they monitored retinal function with electrophysiological assays that quantify how well retinal neurons respond to light. The results showed a measurable shift toward more normal response patterns, indicating that the treated retinas regained function rather than merely delaying degeneration.